质子放疗联合替莫唑胺治疗低级别胶质瘤患者中假性进展及其他治疗相关效应的增加
本研究回顾性分析2005至2015年间接受质子放疗的WHO II级或IDH突变型WHO III级胶质瘤成人患者,评估联合替莫唑胺是否增加假性进展发生率。结果显示质子放疗联合替莫唑胺较单纯质子放疗增加假性进展风险(HR=2.2,p=0.006),而假性进展与总生存改善相关(p=0.02)。
要点
- 质子放疗联合替莫唑胺较单纯质子放疗增加假性进展风险(HR=2.2,p=0.006)。
- 假性进展与总生存改善相关(p=0.02,假性进展作为时变协变量)。
- 进展定义为组织学、新化疗启动或病灶体积较基线增加超过40%。
核心结论
- 质子放疗联合替莫唑胺与低级别胶质瘤患者假性进展增加相关,但出现假性进展的患者倾向于获得更长生存。
研究设计与样本
- 回顾性病历审查与容积MRI分析,纳入2005至2015年间接受质子放疗的初治WHO II级或IDH突变型WHO III级胶质瘤成人患者,共119例。
主要发现
- 质子放疗联合替莫唑胺较单纯质子放疗增加假性进展风险(HR=2.2,p=0.006,Cox单因素分析)。
- 假性进展的存在与总生存改善相关(p=0.02,假性进展作为时变协变量)。
关键数值与推荐
- 进展定义为组织学、新化疗启动或病灶体积较基线增加超过40%。
- 治疗相关效应(PTRE)定义为新发或加重的T2/FLAIR或异常强化,最终消退或稳定且6至12个月无进展证据。
- 假性进展定义为PTRE中可疑进展或体积较基线增加至少40%的亚组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Concurrent radiotherapy and temozolomide (TMZ) is associated with radiographic pseudoprogression (PsP) in glioblastoma. The occurrence of PsP and other treatment effects is less well understood in low-grade gliomas (LGG). The purpose of this study is to evaluate whether the addition of TMZ to radiotherapy increases the incidence of PsP in adults with LGG treated with proton radiotherapy (PRT). METHODS: Chart review and volumetric MRI-analysis was performed on radiotherapy-naive adults with WHO grade II or IDH mutant WHO grade III gliomas treated with PRT between 2005 and 2015. Progression was defined by histology, new chemotherapy initiation, or progressive increase in lesion volume beyond 40% from baseline. Post treatment related effects (PTRE) were defined as new/increased T2/FLAIR or abnormal enhancement which eventually resolved or stabilized without evidence of progression for a period of 6-12 months. PsP was defined as the subset of PRTE suspicious for progression or volumetrically increased at least 40% from baseline. Pearson's chi-squared test and Cox-proportional hazards models were used for statistical analysis. RESULTS: There were 119 patients meeting inclusion criteria. There was an increased risk of PsP following PRT + TMZ versus PRT-alone (HR = 2.2, p = 0.006, on Cox univariate analysis). Presence of PsP was associated with improved OS (p = 0.02 with PsP as time-varying covariate). CONCLUSIONS: TMZ use, when added to PRT, was associated with increased PsP in patients with LGG; however, patients with PsP tended to achieve longer survival.
引用
- Dworkin M, Mehan W, Niemierko A, et al. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2018. PMID: 30488294. doi:10.1007/s11060-018-03063-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。